摘要:

Ten acromegalics received daily doses of 200-300 µg of a long-acting somatostatin analog, SMS 201-995 (Sandostatin, SMS), for an average of 64 weeks. Basal mean GH values of 44 ± (SE) 7.8 ng/ml had fallen into the normal range at the end of the observation period (mean 64 weeks). This effect was accompanied by a substantial drop in somatomedin-C values. Reduction of pituitary tumor size could be documented in 3 of 6 patients. Whereas SMS did not affect high plasma PRL in 4 microprolactinoma patients, lactotrophs turned sensitive to this agent in mixed GH/PRL tumors. In a comparative study between SMS and bromocriptine, the former normalized circulating GH in 10 of 17 acromegalics in an acute trial, whereas bromocriptine was effective in only 5. A combination of both substances was effective in 2 of 3 patients who were insensitive to single drug administration. Cultures of GH-secreting tumor cells showed a statistically significant hormone decrease in the medium when exposed to SMS. However, in some instances, a diminution of the GH contents of the tumor cells was also observed, presumably as the basis for intracellular breakdown and clinical tumor shrinkag

ISSN:1663-2818    

DOI:10.1159/000180984

出版商:S. Karger AG    

年代:1988

数据来源: Karger

摘要:

Experience with SMS 201-995 (Sandostatin), a somatostatin analog, in the treatment of endocrine active gastrointestinal tumors is reviewed. Best immediate results were obtained in vipomas and insulinomas but a scape phenomenon was frequently observed. A positive and persistent effect was recorded in a case of nesidioblastosis. It was striking that good clinical control could be obtained in some instances despite insufficient suppression of hormone secretion by the tumor. This finding suggests peripheral actions of somatostatin and SMS independently of its primary effect on hormone release.

ISSN:1663-2818    

DOI:10.1159/000180985

出版商:S. Karger AG    

年代:1988

数据来源: Karger

摘要:

Inappropriate thyrotropin secretion (1ST) may originate from either neoplastic disease (nIST) or nonneoplastic resistance to thyroid hormone (nnlST). An inhibitory effect of somatostatin on TSH secretion has been documented. In an attempt to elucidate the possible therapeutic effect of this peptide on nIST and nnlST, a study was conducted in 7 such patients. Sandostatin (SMS 201–995) was administered in daily doses of 100 µg for several days to 1 month. Four patients with nIST responded with a fall in circulating TSH as well as α-subunit with concomitant normalization of free thyroxine and clear symptomatic improvement. In the 3 nnlST patients this effect was considerably less apparent and a partial TSH escape was observed on long-term treatment in 2 cases. The importance of somatostatin and its analogs in the management of thyroid malignancy is stres

ISSN:1663-2818    

DOI:10.1159/000180986

出版商:S. Karger AG    

年代:1988

数据来源: Karger

摘要:

The effect os SMS 201-995 (Sandostatin), a long-acting somatostatin analog, on different types of pituitary adenomas including α-subunit elevation is illustrated in this report. Treatment induced a fall in hCG levels in a woman with a pituitary adenoma producing only α-subunit. In 3 acromegalic patients, there was only a partial drop in GH and α-hCG. The same effect was observed in a woman with menopausal FSH and LH levels. SMS reduced plasma TSH and α-hCG in a case of thyrotropic adenoma. Two patients exhibiting FSH- and α-hCG-secreting adenomas did not respond to acute administration of SMS 201–995. More patients have to be treated before a definitive statement can be made on the usefulness of somatostatin analogs in the management of different types of pituitary ad

ISSN:1663-2818    

DOI:10.1159/000180987

出版商:S. Karger AG    

年代:1988

数据来源: Karger

摘要:

Administration of hypothalamic peptides has been reported to induce behavioral changes and to modify neurological functions such as locomotor activity and learning. Somatostatin (SS) and growth hormone-releasing factor (GRF) exert opposite effects on anterior pituitary secretion. Similarly, at the central nervous system (CNS) level, SS and GRF display antagonistic actions on behavioral parameters. The authors were able to confirm these effects in male Wistar rats by means of a computerized electronic maze measuring locomotor activity and learning. SS concentration is reduced in specific areas of the CNS in patients with late onset of senile dementia of the Alzheimer’s type (SDAT). In early onset SDAT a GRF test elicits a growth hormone response much greater than that observed in normal controls of the same age or in patients with late onset SDAT. Thus, administration of GRF to patients with early onset SDAT has been followed by a significant improvement in locomotion, appetite, mental performance and social interaction. A possible therapeutic role of GRF in the management of patients with dementia remains to be explore

ISSN:1663-2818    

DOI:10.1159/000180988

出版商:S. Karger AG    

年代:1988

数据来源: Karger